Zoetis Inc. $ZTS Stake Raised by Rowlandmiller & PARTNERS.ADV

Rowlandmiller & PARTNERS.ADV boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 29.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,328 shares of the company’s stock after acquiring an additional 750 shares during the quarter. Rowlandmiller & PARTNERS.ADV’s holdings in Zoetis were worth $519,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Nuveen LLC bought a new stake in Zoetis in the first quarter worth about $616,375,000. Sarasin & Partners LLP bought a new stake in Zoetis in the first quarter worth about $339,111,000. Mackenzie Financial Corp raised its position in Zoetis by 4,158.3% in the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after acquiring an additional 1,782,110 shares in the last quarter. GAMMA Investing LLC raised its position in Zoetis by 14,731.3% in the first quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company’s stock worth $289,666,000 after acquiring an additional 1,747,423 shares in the last quarter. Finally, Polen Capital Management LLC raised its holdings in Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent analyst reports. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and cut their price objective for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Argus restated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday. Finally, Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Zoetis has a consensus rating of “Moderate Buy” and an average target price of $200.88.

Zoetis Price Performance

Shares of ZTS opened at $148.33 on Friday. The company has a market capitalization of $65.74 billion, a price-to-earnings ratio of 25.53, a P/E/G ratio of 2.42 and a beta of 0.89. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The business’s 50-day moving average is $152.32 and its 200-day moving average is $157.31.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.